| Prev Close | 96.00 |
| Day Low/High | 98.01 / 102.30 |
| 52 Wk Low/High | 46.37 / 137.61 |
Emergent BioSolutions Inc. (EBS)
102.20
NYSE
| Exchange | NYSE |
| Shares Outstanding | 53.30B |
| Market Cap | 5.12B |
| P/E Ratio | 34.33 |
| Div & Yield | N.A. (N.A) |
Latest News
The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events
This Friday several banks begin the unofficial kickoff of 'earnings season'.
Jim Cramer: Bring on the Vaccine, I'm Ready
The sooner that we get jabbed the more likely the economy can spring back to life.
Emergent BioSolutions Could See Further Upside Gains
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
Jim Cramer: This Is Where to Put Your Cash as Covid Surges
Instead of scratching your head and saying the market defies logic, look to the Cramer Covid-19 Index.
Emergent BioSolutions Could Correct Lower
Let's check the charts and come up with a trading strategy.
How to Play Emergent Biosolutions' Continuing Rally
Let's check out the latest charts and indicators.
Vaccine Maker Emergent BioSolutions Could Surge Higher in the Months Ahead
EBS has been in an uptrend for a long time.
Emergent BioSolutions Appears on a Healthy Trajectory
Investors may consider dosing up on the long side of this vaccine provider.
Emergent BioSolutions Looks Like It Will Get a Shot in the Arm
EBS stock is poised to make a tradable rally in the weeks ahead.
Military Might: Top Defense & Security ETF and Stock Picks for a Dangerous World
Seven experts select their best ideas among aerospace and naval contractors, drones, building security, biological threats and cybersecurity.
10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Six Off the Beaten Path Healthcare Stock Gems
These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.
Tip for 2016: Stay Focused on Your Long-Term Vision
Try and remember that life isn't about Jan. 1 through Dec. 31, so why should your returns be?
Stocks Under $10: Stealth Drug Play
Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.
Earnings Continue to Disappoint
Let's see how the manufacturing data stack up over the next 24 hours. On the corporate profit front, earnings continue to be disappointing. Over there, in Europe, UBS (UBS), BP (BP) and Anheuser-Busch InBev (BUD) missed, and their share prices are d...
